浙江佐力药业股份有限公司 机构调研会议材料 会议时间：2014 年 8 月 7 日星期四 会议地点：会议室 B 调研机构：兴业证券 方玉涵；民生证券 张金洋；国鸣投资管理有限公司 马士 高；博时基金 葛晨；招商基金 周洪伟 调研对象：董事长俞有强，董事会秘书郑超一，证券事务代表吴英，证券助理 邱玥 会议记录：吴英 调研要点： 1、乌灵胶囊增速缓慢，增速放缓的原因是什么？对于增速放缓，公司有 什么措施保持销售增长。 答：今年医疗体制改革深化，药品控费成为常态，特别是基药目录、医保 目录、药品价格调整，医保支付方式、医院收费制度、药品招标采购方式等的 不断改革，对药品生产经营造成一定影响，这是大多数医药企业共同面对的问 为了保证业绩稳定增长，公司一是将时刻关注行业政策变化，积极采取应 对措施，以控制和降低生产经营风险；二是在继续关注二级以上医院开发的同 时加强已开发医药的多科室推广；三是通过精细化招商的方式有效利用社会资 源，加快乌灵系列在二级以上医院的覆盖和终端的推广；四是加强人才的引进 和营销团队建设，不断创新营销模式，优化营销渠道，扩大市场销售，寻求突 破。 2、乌灵胶囊销售主要在哪些科室？未来增长点的来源 ...

证券代码：300181 证券简称：佐力药业 浙江佐力药业股份有限公司投资者关系活动记录表 编号：2014-009 | --- | --- | --- | |------------------------|--------------------------------|--------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | √ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 银华基金管理有限公司 魏卓； | | | 人员姓名 | 北京星石投资管理有限公司 方磊. | | | 时间 | 2014 年 8 月 14 | 日 | | 地点 | 佐力药业会议室 | | | | | | | 上市公司接待人 员姓名 | 董事会秘书郑超一，证券助理邱玥 | | | 投资者关系活动 | | 介绍了公司经营情况及企业、产品的基本情况，回答了投资者 | | 主要内容介绍 | 提问 . ...

证券代码：300181 证券简称：佐力药业 编号：2014-010 | --- | --- | --- | |----------------|----------------------------|--------------------------------------------------------| | | □ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | √ 现场参观 | | | | □ 其他 | | | | | 财通证券，杨玥；兴源控股，王威军； | | | | 大成基金，杨强；招商基金，李佳存； | | 参与单位名称及 | | 上海从容投资管理有限公司，涂畅；华夏财富创新投资管理 | | 人员姓名 | | 有限公司，李涛；东吴证券 许希晨；宗毅润邦投资 许俊华； | | | 秦信基金 徐慕浩。 | | | 时间 | 2014 年 8 月 19 | 日；8 月 22 日 | | 地点 | 佐力药业会议室 | | | 上市公司接待人 | | | | 员姓名 | | 董事会秘书郑超一，证 ...

浙江佐力药业股份有限公司 机构调研会议材料 会议时间：2015 年 8 月 18 日 13:30—16:30； 会议地点：公司总部会议室 调研机构：景泰利丰资产管理有限公司，文婷；上海域秀资产管理有限公司； 西南证券，施跃；中投证券，梅梅；上海宏铭投资管理有限公司；上海红象投 资，唐坚；国都证券，姚巍，陈柳，赵玥；勇哲资管；立名投资，许淼；中大 投资，郑秀峰；中航证券，沈文文；上投摩根基金，罗会礼；天马资产，李安； 正京投资，徐文厂；广发资管，毛丁丁；新华汇嘉，蓝小康；苏州贵山财富， | --- | --- | |-------------------------------------------------------------|-------| | | | | 许志强，夏永生；北京中港融鑫资产管理有限公司，李枭立； | | | 调研对象： 董事会秘书郑超一，证券事务代表吴英，证券助理邱玥 | | | 会议记录： 证券事务代表 吴英 | | | 调研要点： | | 1、调研机构观看了公司乌灵参纪录片，董事会秘书向调研机构介绍了乌 灵产品发展历程和上半年的主要经营情况。 答：通过乌灵参纪录片大家可以看到野 ...

证券代码：300181 证券简称：佐力药业 浙江佐力药业股份有限公司投资者关系活动记录表 编号：2015-006 | --- | --- | --- | |------------------------|--------------------------|--------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | √ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 王猛军，秦立轩，弓颜福 | | | 人员姓名 | | | | | | | | 时间 | 2015 年 11 月 16 | 日 | | 地点 | 佐力药业会议室 | | | 上市公司接待人 员姓名 | | 董事会秘书郑超一，证券事务代表吴英 | | 投资者关系活动 | | 介绍了公司经营情况及企业、产品的基本情况，回答了投资者 | | 主要内容介绍 | 提问. | | | 附 件 清 单 （ ...

浙江佐力药业股份有限公司 机构调研会议材料 会议时间：2014 年 11 月 7 日 会议地点：公司一楼会议室 调研机构：上海博观投资管理有限公司,深圳市鼎诺投资管理有限公司 调研对象：董事会秘书郑超一，证券事务代表吴英 会议记录：吴英 调研要点： 1、投资者都非常关心公司乌灵参纪录片，请问什么时候能播放？纪录片 对公司产品的销售有何意义？ 答：公司乌灵参纪录片目前已完成了最后的剪辑，预计年底前可正式播放。 不同于冬虫夏草、灵芝等药用真菌，乌灵参自然资源极为稀少，在老百姓中的 知名度不高，纪录片的播放，一方面有利于大众更全面的了解乌灵参这一珍稀 药用真菌，引起大家的关注和兴趣，挖掘潜在需求；另一方面有利于学术推广 团队更好地向医生传递关于乌灵参的相关信息，如生长环境、自然资源稀缺、 在民间的药用价值和工业化生产的最新进展，树立他们对乌灵系列产品的信心。 2、公司三季度销售收入较前期放缓的原因是什么？ 答：今年医疗体制改革进一步深化，药品控费成为常态，特别是医保支付 方式、医院收费制度、药品招标采购方式等的不断改革，对药品生产经营造成 一定影响，这是大多数医药企业共同面对的问题。乌灵胶囊的增速变化基本符 合口服 ...

证券代码：300181 证券简称：佐力药业 浙江佐力药业股份有限公司投资者关系活动记录表 编号：2014-013 | --- | --- | --- | |-----------------------------|----------------------------|--------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | √ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 上海博观投资 张世栋 毕海委 | | | 人员姓名 | | 深圳市鼎诺投资管理有限公司 胡文锋 | | 时间 | 2014 年 11 月 7 | 日 | | 地点 | 佐力药业 | | | 上市公司接待人 | | | | 员姓名 | | 董事会秘书郑超一，证券事务代表吴英 | | 投资者关系活动 主要内容介绍 | 提问 . | 介绍了公司经营情况及公司、产品的基本情况，回答了投资者 | | 附 ...

浙江佐力药业股份有限公司 机构调研会议材料 会议时间：2015 年 4 月 21 日 10:00—13:00； 会议地点：公司一楼会议室 调研机构：华安基金，裘倩倩；广发证券，吴雅春；中金证券，楼慧源；华泰 柏瑞基金，盛夏；易方达基金，王勇 调研对象:副总经理、营销总部总经理汪涛，董事会秘书 郑超一，证券事务代表 吴英，证券助理 邱 玥 会议记录：吴英 调研要点： 1、请问汪总任职之后，在做好公司营销工作方面有哪些思路？ 答：公司主要从以下三个方面加强营销工作：一是加强自营队伍的建设与 发展，公司收购了珠峰药业以后，在药用真菌领域又拥有了百令片这一拳头产 品，公司将两个药用真菌产品整合到一起，有利于销售人员人均生产力的提高， 有利于自营队伍的建设与巩固；二是逐步实行精细化招商管理，进行招商功能 1 的重组，作为自营队伍的有力补充；三是加强 OTC 销售，构建 OTC 部门与团 队，并于今年 4 月份正式启动，将与国内知名的连锁大药房建立合作，实施大 连锁覆盖的 OTC 策略。 2、汪总在上任后对营销组织和人员有什么大的调整和动作？ 答：考虑到自营销售的稳定性，汪涛副总上任后并未对营销组织和人员进 行大规模的变 ...

Financial Performance - The company's operating revenue for the third quarter was ¥449,454,503.18, an increase of 18.03% compared to the same period last year[7]. - The net profit attributable to shareholders was ¥69,072,832.17, representing a growth of 53.64% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥67,121,875.98, up by 51.04% compared to the previous year[7]. - The company reported a 24.66% increase in operating revenue year-to-date, driven by the strategic focus on its "one body, two wings" strategy and strong sales of the Wuling series[14]. - The company’s diluted earnings per share for the third quarter was ¥0.1135, an increase of 53.59% year-on-year[7]. - The net profit for the current period reached CNY 214,596,952.02, an increase of 52.2% compared to CNY 141,046,881.84 in the previous period[33]. - The total revenue from operating activities was CNY 1,358,686,568.10, up from CNY 1,145,765,464.34, reflecting a growth of 18.6%[36]. - The total profit for the current period was CNY 241,462,425.66, compared to CNY 163,470,420.07, an increase of 47.7%[33]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,528,233,581.92, a decrease of 8.02% from the end of the previous year[7]. - Total current assets rose to ¥1,010,775,134.74, compared to ¥941,671,002.17, marking an increase of about 7.4%[30]. - Non-current assets decreased to ¥1,517,458,447.18 from ¥1,806,861,179.90, a decline of approximately 16.0%[30]. - Total liabilities increased to ¥808,152,229.37 from ¥765,314,231.14, showing a growth of about 5.7%[30]. - The company's total assets decreased to ¥2,528,233,581.92 from ¥2,748,532,182.07, a reduction of approximately 8.0%[30]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥193,904,381.17, reflecting a growth of 4.27% compared to the same period last year[15]. - Cash outflow from investment activities increased by 280.74% year-on-year, totaling ¥62,695,000, primarily due to increased fixed asset investments[15]. - The cash flow from operating activities netted CNY 193,904,381.17, slightly up from CNY 185,971,918.34, showing a growth of 5.0%[36]. - Cash outflow from investment activities totaled $356.58 million, an increase from $208.25 million year-over-year[39]. - Net cash flow from investment activities was -$62.70 million, compared to $34.69 million in the previous year[39]. - The net increase in cash and cash equivalents was -$34.86 million, compared to -$19.80 million year-over-year[39]. - The ending balance of cash and cash equivalents was $179.37 million, down from $222.48 million in the previous year[39]. Research and Development - Research and development expenses for the year-to-date period reached ¥50,502,900, an increase of 58.49% year-on-year, indicating a significant investment in R&D[14]. - Research and development expenses increased to CNY 50,502,876.94, compared to CNY 31,864,624.60, marking a rise of 58.5%[33]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 43,301[21]. - The largest shareholder, Yu Youqiang, holds 21.34% of the shares, amounting to 129,890,463 shares[21]. - The major shareholder, Deqing County Cultural Tourism Development Group Co., Ltd., plans to transfer 31,296,821 shares, representing 5.14% of the total share capital, at a price not lower than RMB 10 per share[23]. Acquisitions and Approvals - The company acquired a 48.99% stake in Zhejiang Zoli Baicao Traditional Chinese Medicine Co., Ltd. for RMB 75 million, making it a wholly-owned subsidiary[22]. - The company received approval from the China Securities Regulatory Commission for a specific stock issuance, with the board set to proceed according to regulations[23]. - The company has completed the necessary industrial and commercial change registration related to the acquisition of the subsidiary[22]. Other Financial Metrics - The weighted average return on net assets was 3.31%, an increase of 0.86% compared to the previous year[7]. - The company's sales expenses increased to CNY 625,185,175.62 from CNY 527,256,206.19, reflecting a rise of 18.6%[33]. - The company reported a significant increase in investment income, which rose to CNY 2,184,971.15 from CNY 801,339.44, representing a growth of 172.5%[33]. - The total comprehensive income for the current period was CNY -49,959,988.87, a decrease from CNY 750,851,834.92 in the previous period[35]. - The company reported a decrease in other comprehensive income, with a net amount of CNY -264,556,940.89 compared to CNY 609,804,953.08 in the previous period[33]. Audit and Reporting - The third quarter report was not audited[40]. - The report was issued by the board of directors of Zhejiang Zuoli Pharmaceutical Co., Ltd.[41].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥894,948,098.95, representing a 28.28% increase compared to ¥697,672,446.16 in the same period last year[26]. - The net profit attributable to shareholders was ¥134,887,213.05, a 55.83% increase from ¥86,560,659.13 in the previous year[26]. - The net profit after deducting non-recurring gains and losses was ¥130,543,414.51, up 58.79% from ¥82,211,552.19 year-on-year[26]. - The net cash flow from operating activities was ¥132,222,204.29, an increase of 41.29% compared to ¥93,581,105.14 in the same period last year[26]. - Basic earnings per share rose to ¥0.2216, a 55.84% increase from ¥0.1422 in the previous year[26]. - The total profit reached 160.33 million yuan, reflecting a year-on-year growth of 51.37%[56]. - The company reported a total non-recurring profit of 4,343,798.54 CNY after accounting for tax and minority interests[32]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,526,678,794.55, down 8.07% from ¥2,748,532,182.07 at the end of the previous year[26]. - Net assets attributable to shareholders decreased by 9.95% to ¥1,660,671,813.22 from ¥1,844,064,465.20 at the end of the previous year[26]. - The total amount of financial assets at fair value through profit or loss decreased from RMB 65,517,700.00 to RMB 14,657,400.00, a decline of approximately 78%[189]. - Total liabilities decreased from ¥765,314,231.14 to ¥751,686,399.42, a decline of approximately 1.6%[195]. - Current liabilities increased from ¥584,575,315.41 to ¥643,055,134.14, an increase of approximately 10.0%[195]. Market Position and Product Development - The company's leading product, Wuling Capsule, ranked 1st in the urban community health center market for neurological disease medications in 2021, with a market share of 11.88%[38]. - Wuling Capsule also ranked 1st in county-level public hospitals for the same category, increasing its market share from 6.74% in 2020 to 8.27% in 2021[41]. - The company successfully launched a new product, Polycarbophil Calcium Tablets, during the reporting period[43]. - The Chinese traditional medicine market is projected to grow to 1,137.5 billion CNY by 2024, indicating a strong growth opportunity for the company[38]. - The company was ranked 56th in the "Top 100 Chinese Traditional Medicine Enterprises" list for 2021, reflecting its solid market position[41]. - The company has implemented a series of strategies to enhance its R&D capabilities and market expansion, aligning with national policies supporting traditional medicine[38]. Research and Development - Research and development investment surged by 88.40% to ¥31,975,423.75, focusing on the clinical value of the Wuling series products and the development of new traditional Chinese medicine products and technologies[67]. - The company is focusing on innovation and R&D, particularly in the areas of Alzheimer's treatment and traditional Chinese medicine standards[58]. - The company is increasing investment in the research and development of traditional Chinese medicine formula granules to capitalize on market opportunities[51]. - The company has established a comprehensive quality management system to enhance production quality and efficiency[57]. Risk Management and Compliance - The company has outlined potential risks and countermeasures in its management discussion and analysis section[5]. - The company has identified risks related to industry policy changes and is actively monitoring and adapting to these changes to maintain competitiveness[100]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[114]. - The company has established an ISO 14001 environmental management system since 2004, which has been operational for over 10 years, emphasizing green development as a key management strategy[119]. Corporate Governance and Social Responsibility - The company has revised multiple internal governance documents, including the Articles of Association and various management rules, to enhance compliance and governance[115]. - The company actively engages in social responsibility initiatives, conducting various public welfare activities, including online and offline events focused on sleep disorders and mental health[119]. - The company maintains a 100% labor contract signing rate and regularly pays labor remuneration, ensuring full social insurance and housing fund contributions for all employees[118]. Shareholder and Investment Activities - The company plans to raise up to 910 million yuan through a private placement to fund projects including the construction of an intelligent traditional Chinese medicine production base and upgrades to the R&D center[59]. - The company completed the acquisition of an 8% stake in Zhejiang Top Pharmaceutical Co., Ltd. from shareholder Yu Yin, with the transfer registered at the China Securities Depository and Clearing Corporation[153]. - The company approved the acquisition of a total of 48.99% equity from minority shareholders Chen Huan and Chen Zhaorong in its subsidiary Zhejiang Zali Baicao Chinese Medicine Co., Ltd. for 75 million RMB, with the process still ongoing[153].